These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29930260)

  • 1. New treatments and therapeutic targets for IBS and other functional bowel disorders.
    Simrén M; Tack J
    Nat Rev Gastroenterol Hepatol; 2018 Oct; 15(10):589-605. PubMed ID: 29930260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel pharmacological therapies for irritable bowel syndrome.
    Corsetti M; Whorwell P
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):807-15. PubMed ID: 26907518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
    Kane JS; Ford AC
    Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irritable Bowel Syndrome: What Treatments Really Work.
    Alammar N; Stein E
    Med Clin North Am; 2019 Jan; 103(1):137-152. PubMed ID: 30466670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
    Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
    Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
    Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discovery approaches to irritable bowel syndrome.
    Hornby PJ
    Expert Opin Drug Discov; 2015; 10(8):809-24. PubMed ID: 26193876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.
    Camilleri M; Ford AC
    Handb Exp Pharmacol; 2017; 239():75-113. PubMed ID: 27995391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
    Scarpignato C; Pelosini I
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ▼ Eluxadoline for IBS-D.
    Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irritable bowel syndrome: a clinical review.
    Chey WD; Kurlander J; Eswaran S
    JAMA; 2015 Mar; 313(9):949-58. PubMed ID: 25734736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
    Harris LA; Baffy N
    Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
    Corsetti M; Whorwell P
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):285-292. PubMed ID: 28276811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.
    Lee HJ; Choi JK; Ryu HS; Choi CH; Kang EH; Park KS; Min YW; Hong KS
    J Neurogastroenterol Motil; 2017 Jan; 23(1):9-19. PubMed ID: 28049862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probiotics in functional bowel disorders.
    Hod K; Ringel Y
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):89-97. PubMed ID: 27048900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.